Syndax Pharmaceuticals Inc SNDX
Syndax Pharmaceuticals Inc (Nasdaq: SNDX) is an oncology drug developer. Its lead program, Revuforj (revumenib), is in Phase 3 for relapsed/refractory acute leukemia with KMT2A translocation; R/R NPM1-mutant AML. Its next catalyst on record is axatilimab + ruxolitinib (newly diagnosed cGVHD): Phase 2 topline data (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: axatilimab + ruxolitinib (newly diagnosed cGVHD) — Phase 2 topline data (Q4 2026). 11 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Revuforj (revumenib) | R/R KMT2Ar acute leukemia; R/R NPM1m AML | small molecule | Approved |
| Niktimvo (axatilimab-csfr) | chronic GVHD after failure of at least two prior lines | antibody | Approved |
| revumenib EVOLVE-2 | newly diagnosed NPM1m/KMT2Ar AML, unfit for intensive chemo | small molecule | Phase 3 |
| revumenib REVEAL-ND | newly diagnosed NPM1m AML with intensive chemotherapy | small molecule | Phase 3 |
| axatilimab + corticosteroids (pivotal) | newly diagnosed chronic GVHD | antibody | Phase 3 |
| axatilimab + ruxolitinib | newly diagnosed chronic GVHD | antibody | Phase 2 |
| axatilimab MAXPIRe | idiopathic pulmonary fibrosis | antibody | Phase 2 |
| revumenib RAVEN | newly diagnosed KMT2Ar AML, fit for intensive chemo | small molecule | Phase 2 |
| revumenib MenTain | post-transplant maintenance | small molecule | Phase 2 |
| revumenib in myelofibrosis | myelofibrosis | small molecule | Phase 1 |
| SNDX-4321 | EGFR-mutant NSCLC | small molecule | Pre-clinical |
| SNDX-62122 | myelofibrosis (next-generation menin inhibitor) | small molecule | Pre-clinical |
Recent results and decisions
- Feb 26, 2026completed enrollment Completed enrollment in the MAXPIRe Phase 2 IPF trial of axatilimab in Q1 2026.
Completed enrollment in MAXPIRe, a Phase 2, 26-week randomized, double-blinded, placebo-controlled trial of axatilimab on top of standard of care in patients with idiopathic pulmonary fibrosis (IPF) in the first quarter of 2026.
Filing - Jan 12, 2026started REVEAL-ND Phase 3 of revumenib plus intensive chemotherapy in newly diagnosed NPM1m AML initiated in November 2025, with dual primary endpoints MRD-negative CR and EFS.
Initiated REVEAL-ND, a Phase 3, randomized, double-blind, placebo-controlled trial of revumenib in combination with intensive chemotherapy in newly diagnosed patients with NPM1m AML in November 2025.
Filing - Oct 24, 2025approval FDA approved Revuforj for R/R NPM1-mutated AML in adults and pediatric patients 1 year and older, based on 23% CR+CRh (15/65).
the U.S. Food and Drug Administration (FDA) has approved Revuforj (revumenib) for the treatment of relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 (NPM1) mutation in adult and pediatric patients one year and older who have no satisfactory alternative trea
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 oncology companies
- Merck & Co., Inc. MRK
- Astrazeneca PLC AZN
- Bristol Myers Squibb Co BMY
- BeOne Medicines Ltd. ONC
- Revolution Medicines, Inc. RVMD
- Genmab A/S GMAB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.